Clearstead Advisors, LLC Bristol Myers Squibb CO Transaction History

Clearstead Advisors, LLC

$6.31 Billion
Q3 2024

A detailed history of Clearstead Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Clearstead Advisors, LLC holds 120,732 shares of BMY stock, worth $6.96 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

120,732

Previous 123,551 2.28%

Holding current value

$6.96 Million

Previous $5.13 Million 21.75%

% of portfolio

0.1%

Previous 0.09%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$39.66 - $51.75 $111,801 - $145,883	-2,819 Reduced 2.28%	120,732 $6.25 Million
Q2 2024 Aug 09, 2024	BUY	$40.25 - $52.99 $2.55 Million - $3.36 Million	63,325 Added 105.15%	123,551 $5.13 Million
Q1 2024 May 14, 2024	SELL	$47.98 - $54.4 $315,420 - $357,625	-6,574 Reduced 9.84%	60,226 $3.27 Million
Q4 2023 Feb 12, 2024	SELL	$48.48 - $57.85 $595,819 - $710,976	-12,290 Reduced 15.54%	66,800 $3.43 Million
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $101,075 - $113,018	-1,746 Reduced 2.16%	79,090 $4.59 Million
Q3 2023 Nov 07, 2023	BUY	$57.89 - $64.73 $330,899 - $369,996	5,716 Added 7.61%	80,836 $4.69 Million
Q2 2023 Aug 07, 2023	SELL	$63.71 - $70.74 $34,467 - $38,270	-541 Reduced 0.72%	75,120 $4.8 Million
Q1 2023 May 09, 2023	SELL	$65.71 - $74.53 $6,702 - $7,602	-102 Reduced 0.13%	75,661 $5.24 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $340,482 - $403,179	4,972 Added 7.02%	75,763 $5.45 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $525 - $310,664	-4,043 Reduced 5.4%	70,791 $5.03 Million
Q2 2022 Aug 12, 2022	SELL	$72.62 - $79.98 $15,540 - $17,115	-214 Reduced 0.29%	74,834 $5.76 Million
Q1 2022 May 04, 2022	BUY	$61.48 - $73.72 $56,930 - $68,264	926 Added 1.25%	75,048 $5.48 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $73,419 - $85,589	1,369 Added 1.88%	74,122 $4.62 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $83,015 - $97,241	1,403 Added 1.97%	72,753 $4.31 Million
Q2 2021 Aug 12, 2021	BUY	$61.91 - $67.42 $441,170 - $480,434	7,126 Added 11.1%	71,350 $4.77 Million
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $308,568 - $347,048	5,200 Added 8.81%	64,224 $4.05 Million
Q4 2020 Feb 11, 2021	SELL	$57.74 - $65.43 $77,718 - $88,068	-1,346 Reduced 2.23%	59,024 $3.66 Million
Q3 2020 Nov 12, 2020	SELL	$57.43 - $63.64 $421,536 - $467,117	-7,340 Reduced 10.84%	60,370 $3.64 Million
Q2 2020 Aug 11, 2020	BUY	$54.82 - $64.09 $572,594 - $669,420	10,445 Added 18.24%	67,710 $3.98 Million
Q1 2020 May 14, 2020	SELL	$46.4 - $67.43 $308,977 - $449,016	-6,659 Reduced 10.42%	57,265 $3.19 Million
Q4 2019 Feb 11, 2020	BUY	$49.21 - $64.19 $850,890 - $1.11 Million	17,291 Added 37.08%	63,924 $4.1 Million
Q3 2019 Nov 12, 2019	SELL	$42.77 - $50.71 $72,709 - $86,207	-1,700 Reduced 3.52%	46,633 $2.37 Million
Q2 2019 Aug 08, 2019	SELL	$44.62 - $49.34 $80,449 - $88,960	-1,803 Reduced 3.6%	48,333 $2.19 Million
Q1 2019 May 14, 2019	SELL	$45.12 - $53.8 $163,244 - $194,648	-3,618 Reduced 6.73%	50,136 $2.39 Million
Q4 2018 Feb 11, 2019	SELL	$48.76 - $63.23 $89,913 - $116,596	-1,844 Reduced 3.32%	53,754 $2.79 Million
Q3 2018 Nov 13, 2018	SELL	$55.19 - $62.25 $304,372 - $343,308	-5,515 Reduced 9.02%	55,598 $3.45 Million
Q2 2018 Aug 07, 2018	SELL	$50.53 - $62.98 $18,392 - $22,924	-364 Reduced 0.59%	61,113 $3.38 Million
Q1 2018 May 14, 2018	BUY	$59.92 - $68.98 $175,925 - $202,525	2,936 Added 5.02%	61,477 $3.89 Million
Q4 2017 Feb 09, 2018	BUY	$59.94 - $65.35 $23,016 - $25,094	384 Added 0.66%	58,541 $3.59 Million
Q3 2017 Nov 09, 2017	BUY	$55.23 - $63.74 $3.21 Million - $3.71 Million	58,157	58,157 $3.71 Million

Others Institutions Holding BMY

# of Institutions

2,537

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearstead Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearstead Advisors, LLC with notifications on news.

Account

Clearstead Advisors, LLC Bristol Myers Squibb CO Transaction History